Расширенный поиск


Полный текст:


Блокаторы кальциевых каналов в нефропротекции.

Об авторах

В. А. Добронравов
научно-исследовательский институт нефрологии, Санкт-Петербургский государственный медицинский университет им.акад. И.П.Павлова
Кафедра пропедевтики внутренних болезней

О. В. Царькова
научно-исследовательский институт нефрологии, Санкт-Петербургский государственный медицинский университет им.акад. И.П.Павлова
Кафедра пропедевтики внутренних болезней

Список литературы

1. Berridge MJ. Inositol trisphosphate and calcium signaling. Nature 1993; 361: 315325

2. Clapham DE. Calcium signaling. Cell 1995; 80: 259268

3. Brady HR, Brenner BM, Lieberthal W. Acute Renal Failure. In: Brenner BM (ed.) The kidney. Vol. 2, 5th ed.Saunders WB, Philadelphia e.a.;1996:12131214

4. Tsien RW, Hess P, McCleskey EW et al. Calcium channels: Mechanisms of selectivity, permeation and block. Ann Rev Biophys Biophys Chem 1987; 16: 265290

5. Nayler WG. Calcium channels and their involement in cardiovascular disease. Biochem Pharmacol 1992; 43(1) : 3946

6. Schwartz A. Molecular and cellular aspect of calcium channel antagonism. Am J Cardiol 1992; 70: 6f8f

7. Walsh KB, Bryant RE, Schwartz A. Effect of calcium antagonst drugs on calcium currents in mammalian skeletal muscle fibers. J Pharmacol Exp Ther 1986; 236(2): 403407

8. Finkel MS, Patterson RE, Roberts WC et al. Calcium channels binding characteristics in the human heart. Am J Cardiol 1988; 62(17): 12811284

9. Walker B. Evidence for uneven distribution of Ltype calcium channels in rat pulmonary circulation. Am J Physiol 1995; 269: H2051H2056

10. Katz AM. Molecular biology of calcium channels in the cardiovascular system. Am J Cardiol 1997; 80(9A): 17I22I

11. Lijnen P, Petrov V. Proliferation of human peripheral blood mononuclear cells during calcium entry blockade. Role of proteinkinase C. Methods Find Exp Clin Pharmacol 1999; 21(4): 253259

12. Triggle DJ. Pharmacologic and therapeutic difference among calcium channel antagonists: Profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996;78 [Suppl 9A]: 712

13. Riley J, Wilton LV, Shakir SA. A postmarketing observational study to assess the safety of mibefradil in the community in England. Int J Clin Pharm & Ther 2002; 40(6): 241248

14. Siepmann M, Kirch W. Drugdrug interactions of new active substances: mibefradil example. Eur J Clin Pharmacol 2000; 56(3): 273

15. Levine TB, Bernink PJ, Caspi A et al. Effect of mibefradil, a Ttype calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH1 study. Mortality assessment in congestive heart failure trial. Circulation 2000; 101(7): 758764

16. Arima S, Ito S, Omata K et al. Diverse effects of calcium antagonists on glomerular hemodynamics. Kidney Int 1996; 49 [Suppl 55]: S132–S134

17. Ozawa Y, Hayashi K, Nagahama T et al. Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol 1999; 33: 243–247

18. Nakamura A, Hayashi K, Fujiwara K et al. Distinct action of aranidipine and its metabolite on renal microvessels with special reference to renal protection. J Cardiovasc Pharmacol 2000; 35: 942–948

19. Pitt B. Diversity of calcium antagonists. Clinical Therapeutics 1997; 19 [Suppl A]: 317

20. Kleinbloesem CH, Van Brummelen P, Danhof M et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 2630

21. Kramer HJ, MeyerLehnert H, Mohaupt M. Role of calcium in the progression of renal disease: experimental evidence. Kidney Int 1992; 36[Suppl]:S2S7

22. McNally P G, Feehally J. Pathophysiology of cyclosporin A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 1992; 7: 791 804

23. Anderson S, Rennke HG, Brener BM. Nifedipine versus fosinopril in uninephrectomised diabetic rats. Kidney Int 1992; 41(4): 891897

24. Shike T, Tashiro K, Gohda T et al. Effect of calcium channel blockers, nifedipine and benidipine, on death of cultured mouse mesangial cells. Kidney Blood Press Res 2000; 23(2): 126132

25. Navar LG. Integrating multiple paracrine regulators of renal microvascular dynamics. Am J Physiol Renal Physiol 1998; 274(3): F433 – 444

26. Zanchi A, Brunner HR, Waeber B et al. Renal hemodynamic and protective effects of calcium antagonists in hypertension. Hypertens 1995; 13: 13631375

27. Fleming JT, Parekh N, Steinhausen M. Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol. 1987; 253: F1157–F1163

28. Griffin KA, Picken MM, Bidani AK. Deleterius effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 1995; 96: 793800

29. Kvam FI, Ofstad J, Iverson BM. Effects of antihypertensive drugs on autoregulation of RBF and glomerular capillary pressure in SHR. Am J Physiol 1998; 275: F576F584

30. Griffin KA, Picken MM, Bakris GL et al. Class differences in the effects of calcium channel blockers in the rat remnant kidney model. Kidney Int 1999; 55: 18491860

31. Brenner B, Mackenzie H. Nephron mass as a risk factor for progression of renal disease. Kidney Int 1997; 52 [Suppl 63]: 124127

32. Fellner SK, Arendshorst WJ. Capacitative calcium entry in smooth muscle cells from preglomerular vessels. Am J Physiol Renal Physiol 1999; 277(4): F533 – 542

33. Ruan X, Arendshorst WJ. Calcium entry and mobilisation signaling pathway in ANG II induced renal vasoconstriction in vivo. Am J Phiol 1996; 270: f398f405

34. Berridge MJ. Capacitative calcium entry. Biochem J 1995; 312: 111

35. Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KClinduced depolarization on afferent and efferent arterioles. Am J Physiol 1989; 257: F561–F564

36. Carmines PK, Fowler BC, Bell PD. Segmentally distinct effects of depolarization on intracellular [Ca2+] in renal arterioles. Am J Physiol 1993; 265: F677–F685

37. Hansen PB, Jensen BL, Andreasen D et al. Differential expression of T and Ltype voltagedependent calcium channels in renal resistance vessels. Circ Res 2001; 89(7): 630 – 638

38. Ozawa Y, Hayashi K, Nagahama T et al. Effect of Ttype selective calcium antagonist on renal microcirculation studies in the isolated perfused hydronephrotic kidney. Hypertension 2001; 38: 343

39. Hermsmeyer K, Miyagawa K. Protein kinase C mechanism enhances vascular muscle relaxation by the Ca2+ antagonist, Ro 405967. J Vasc Res 1996; 33: 71–77

40. Feng MG, Li M, Gabriel L. Ttype calcium channels in the regulation of afferent and efferent arterioles in rats. Am J Physiol Renal Physiol 2004; 286: F331F337

41. Ozawa Y, Hayashi K, Nagahama T et al. Renal afferent and efferent arteriolar dilation by nilvadipine: studies in the isolated perfused hydronephrotic kidney. J Cardiovasc Pharmacol 1999; 33: 243–247

42. Fujiwara K, Hayashi K, Kanno Y et al. Renal protective effects of efonidipine hydrochloride in subtotally nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 23: 295–312

43. Maki DD, Ma JZ, Louis TA et al. Longterm effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995; 155: 10731080

44. Remuzzi A, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2 15

45. Perna A, Remuzzi A. Abnormal permeability to protein and glomerular lesions a: metaanalysis of experimental and human studies. Am J Kidney Dis 1996; 27(1): 344124

46. Giuseppe D’Amico, Claudio Bazzi. Pathophysiology of proteinuria. Kidney Int 1996; 63(3): 809825

47. Bakris GL, Mehler P, Schrier R. Hypertension and diabetes. In: Schrier RW, Gottschalk CW (eds.) Disease of the Kidney. 6th ed. Little Brown and Company; 1996: 14551464

48. Bakris GL. Hypertension in diabetic patients: An overview of interventional studies to preserve renal function. Am J Hypertens 1993; 6(4): 104s147s

49. Baleris GL. Calcium channel blockers: are they all created equally with regard to slowing progression of diabetic nephropathy? In: Epstein M (ed.) Calcium Antagonists in Clinical Medicine. 2nd ed. Hanley & Belfus, Philadelphia;1996

50. Hebert LA, Bain RP, Verme D et al. For the Collaborative Study Group. Remission of nephrotic range proteinuria in type I diabetes. Kidney Int 1994; 46: 16881693

51. Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 1998; 54: 889896

52. Tarif N, Bakris GL. Preservation of renal function: the spectrum of effects by calcium channel blockers. Nephrol Dial Transplant 1997; 12(11): 22442250

53. PerezReyes E, Schneider T. Molecular biology of calcium channels. Kidney Int 1995; 48: 11111124

54. Jyothirmayi GN, Reddi AS. Effect of diltiazem on glomerular heparan sulfate and albuminuria in diabetic rats. Hypertension 1993; 21(6 pt 1): 795802

55. Gaber L, Walton C, Brown S et al. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidney Int 1994; 46: 161169

56. Sweeney C, Shultz P, Raji L. Interactions of the endothelium and mesangium in glomerular injury. J Am Soc Nephrol 1990;1[Suppl]:S13S20

57. Schultz P, Raij L. Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990; 15 [Suppl 2]: 176180

58. Dworkin LD, Levin RI, Benstein JA et al. Effects of nifedipine and enalapril on glomerular injury in rat with deoxycorticosteronesalt hypertension. Am J Physiol 1990; 259: 598604

59. Dworkin LD, Benstein JA, Parker M et al. Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidn Int 1993; 43: 808814

60. Gaber L, Walton C, Brown S et al. Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized dogs. Kidn Int 1994; 46:161169

61. Dworkin LD, Feiner HD, Parker M et al. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 1991; 39: 11121117

62. Dworkin LD. Effects of calcium antagonists on glomerular hemodynamics and structure in experimental hypertension. Am J Kidney Dis 1991; 17: 8993

63. Ono T, Liu N, Kusano H et al. Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases. Am J Nephrol 2002; 22(56): 581586

64. Zeitler H, Ko Y, Glodny B et al. Cellcycle arrest in G0/ G1 phase of growth factorinduced endothelial cell proliferation by various calcium channel blockers. Cancer Detect Prev 1997; 21(4): 332339

65. Duque I, Rodriguez PM, Ruiz P et al. Calcium channel blockers inhibit hydrogen peroxideinduced proliferation of cultured rat mesangial cells. Pharmacol Exp Ther 1993; 267(2): 612616

66. Orth SR, Nobiling R, Bonisch S et al. Inhibitory effect of calcium channel blockers on human mesangial cell growth: evidence for actions independent of Ltype Ca2+ channels. Kidney Int 1996; 49(3): 868879

67. Ahmed A, Kobayashi S, Shikasho T et al. Differential effects of Ca2+ channel blockers on Ca2+ transients and cell cycle progression in vascular smooth muscle cells. Eur J Pharmacol 1998; 344(23): 323331

68. Sugiura T, Imai E, Moriyama T et al. Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP1 and CREB activities. Nephron 2000; 85(1): 7180

69. Hayashi M, Yamaji Y, Nakazato Y et al.The effects of calcium channel blockers on nuclear factor kappa B activation in the mesangium cells. Hypertens Res 2000; 23(5): 521525

70. Ruan XZ, Varghese Z, Fernando R et al. LDL receptor gene expression in human mesangial cells under the influence of calcium channel blockers. Clin Nephrol 1999; 51(5): 263271

71. Baylis C, Qiu C, Engels K. Comparison of Ltype and mixed L and Ttype calcium channel blockers on kidney injury caused by deoxycorticosteronesalt hypertension in rats. Am J Kidney Dis 2001; 38(6): 12921297

72. Agrotis A, Little PJ, Saltis J et al. Dihydropyridine Ca2+ channel antagonists inhibit the salvage pathway for DNA synthesis in human vascular smooth muscle cells. Eur J Pharmacol 1993; 244(3): 26927

73. Brazy PC, Stead WW, Fitzwillian JF. Progression of renal insufficiency: Role of blood pressure. Kidn Int 1989;35(2):670 674

74. Klahr S. Prevention of progression of nephropathy. Nephrol Dial Transplant 1997;12 [Suppl 2]:6366

75. Klahr S. Role of dietary protein and blood pressure in the progression of renal disease. Kidney Int 1996;49(6):1783 1786

76. Brenner BM. The history and future of renoprotection. Kidney Int 2003; 64(4): 1163

77. Locatelli F, Carbarns I, Maschio G et al. Longterm progression of chronic renal insufficiency in the AIPRI Extension Study. Kidney Int 1997; 52 [Suppl 63]: 6366

78. Anderson S, Rennke HG, Garcia DL et al. Short and longterm effects of antihypertensive therapy in the diabetic rat. Kidney Int 1989; 36: 526536

79. Bakris GL. Abnormalities of calcium and the diabetic hypertensive patients: Implications for renal preservation. Calcium antagonists in clinical medicine. Ed . M. Epsteun. Philadelfia: Hanley & Belfus; 1992: 367389

80. Cortes P, Riser BL, Zhao X et al. Glomerular volume expansion and mesangial cell mechanical strain mediators of glomerular pressure injury. Kidney Int 1994; 45[Suppl]: 811816

81. Malec AM, Gibbons GH, Dzau VJ et al. Fluid shear stress differentially modulates expression of genes encoding basic fibroblast growth factor and platelet derived growth factor B chain in vascular endotheline. J Clin Invest 1993; 92: 20132021

82. Blood pressure lowering treatment trialists ‘Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood pressurelowering drugs; result of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists ‘Collaboration Lancet 2000; 356: 19551964

83. Zannad F, Boivin JM, Lorraine. General Physician Investigators Group. Ambulatory 24–h blood pressure assessment of the felodipine–metoprolol combination versus amlodipine in mild to moderate hypertension. J Hypertens 1999; 17: 1023–1032

84. Jick H, Derby LE, Gurewich V et al. The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996; 16: 321–326

85. Singh V, Christiana J, Frishman WH. How to use calcium antagonists in hypertension: putting the JNCVI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Drugs 1999; 58(4): 579587

86. Haisa S, Norii T, Takatori E et al. Effects of angiotensin converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive noninsulindependent diabetic patients with microalbuminuria. J Diabet Compl 1991; 5:162 164

87. Rosenthal T. Role of calcium channel blocker in the future, in view of the INSIGHT Study. Kidney Int 2002; 62 [Suppl 82]: 3237

88. Stassen JA, Fagard R, Thijs L et al. Randomized double blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 754764

89. Tan LB, Murray RG, Littler WA. Felodipine in patients with chronic congestive heart failure. Discrepant haemodynamic and clinical effects. Br Heart J 1987;58:122 128

90. Packer M. Calcium antagonists in chronic heart failure. Circulation 1990;82:22542257

91. Han P, Boatwright C, Ardlie N. Effect of the calcium entry blocking agent nifedipine on activation of human platelets and comparison with verapamil. Thromb Haemost 1983; 50: 513517

92. Bernini F, Fantoni M, Corsini A et al. «In vitro» inhibition of arterial myocyte growth and stimulation of low density lipoprotein metabolism by SIM 6080, a new calcium antagonist. Pharmacol Res 1990; 22: 2735

93. Pauletto P, Scannapiesco G, Vescovo G et al. Atherosclerosis in cholesterolfed, nifedipineptreated rabbits: «in vivo» and «in vitro» studies. In: Hypertension and Atherosclerosis. Rome: CIC Edizioni Internationale;1988: 2936

94. Rostagno C, Prisco D, Paniccia R et al. Effects of calcium channel blockers on platelet aggregation and thromboxane A2 formation: an in vivo double blind randomized study. Thromb Res 1990; 59: 531539

95. Nakashima Y, Kawashima T, Nandate H et al. Sustained release nifedipine (nifedipine – L) suppresses plasma thromboxane B2 and 6ketoprostaglandin F1± both young male smokers and non smokers. Am Heart J 1990; 119: 12671273

96. Weiss K, Fitscha P, O’Grady J et al. Isradipine: a potent calcium blocker with beneficial effects on platelet function and vascular prostacyclin production. Thromb Res 1989; 54:311 317

97. Busse R, Mulsch A, Fleming I et al. Mechanisms of nitric oxide release from the vascular endothelium. Circulation 1993; 87 [Supp V]: V18V25

98. Sengelov H, Winther K. Effects of felodipine, a new calcium antagonists, on platelet function and fibrinolytic activity at rest and after exercise. Eur J Clin Pharmacol 1989; 37: 453 457

99. Pahor M, Psaty BM, Alderman MH et al. Health outcomes associated with calcium antagonists compared with other firstline antihypertensive therapies: metaanalysis of randomized control trials. Lancet 2000; 356: 19491954

100. Grossman E, Golbourt U. Metaanalyses of antihypertensive therapy: are some of them misleading. Curr Hypert Rep 2001; 3: 381386

101. Magometschnigg D, Hortnagel H, Rameis H Dilthiazem and verapamil: functional antagonism of exogeneous noradrenaline and angiotensin II in man. Eur J Clin Pharmacol 1984; 26: 303307

102. Hjemdahl P, Wallen N. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 [Suppl A]: A36A50

103. Leenen F, Holliwell D. Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992; 69: 639645

104. Sabbah HN, Kono T, Stein PD et al. Left ventricular shape changes during the course of evolving heart failure. Am J Physiol 1992; 263:H266H270

105. Wallen N, Held C, Rehnqvist N et al. Platelet aggregability in vivo is attenuated by verapamil but not by metoprolol in patients with stable angine pectoris. Am J Cardiol 1995; 75: 16

106. Katzman P, Henningsen N, Fagher B et al. Renal and endocrine effects of longterm converting enzyme inhibition as compared to calcium antagonism in essential hypertension. J Cardiovasc Pharmacol 1990; 15: 360364

107. Heinrнch JK, Amanda JB, Frans TH et al. Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers? Kidney Int 1998; 53(6): 15591570

108. Cappuccio FP, Markandu ND, MacGregor GA. Calcium antagonists and sodium balance: Effect of changes in sodium intake and the addition of a thiazide diuretic on the blood pressure lowering effect of nifedipine. J Cardiovasc Pharm 1987; 10 [Suppl 10]: 5760

109. RedonMas J, AbellanAleman J, ArandraLara P et al. Antihypertensive activity of verapamil: Impact of dietary sodium. J Hypertens 1993; 11: 665671

110. Tobe S, Epstein M. The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Cur Hyper Rep 2002; 4(3): 191194

111. Peterson JC, Sharon A, Burkart JM et al. For the Modification of Diet in Renal Disease (MDRD) Study Group: Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann Int Med 1995 ; 123:754762

112. Klahr S, Levey AS, Beck GJ et al. For the modification of diet in renal disease study (MDRD) group: The effects of dietary protein restriction and bloodpressure control on the progression of chronic renal disease. N Eng J Med 1994; 330: 877884

113. Gansevoort RT, Dezeeuw D, Dejong PE. Longterm benefits of antiproteinuric effect of angiotensin converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 1993; 22: 202206

114. Rossing P, Hommel E, Smidt UM et al. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511516

115. Lewis EJ, Hunsicker LG, Raymond PB et al. The effect of angiotensinconvertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 14561462

116. Gansevoort RT, de Zeeuw D, de Jong PE. Longterm benefits of the antiproteinuric effect of ACE inhibition in non diabetic renal disease. Am J Kidney Dis 1993; 2: 202206

117. Maschio G, Alberti D, Janin G et al. The Angiotensin ConvertingEnzyme Inhibition in Progressive Renal Insufficiency Study Group: Effect of the angiotensinconvertingenzyme inhibitor benazepril on the progression of chronic renal iInsufficiency. N Engl J Med 1996; 334: 939945

118. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebocontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 18571863

119. Carmines PK, Ohishi K, Ikenaga H. Functional impairment of renal afferent arteriolar voltagegated calcium channels in rats with diabetes mellitus. J Clin Invest 1996; 98(11): 2564 – 2571

120. Bakris G, Copley J, Vicknair N et al. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50(5): 16411650

121. Bakris G, Mangrum A, Copley J et al. Effect of calcium channel or betablockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29(3): 744750

122. Slataper R, Vicknair N, Sadler R et al. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973 980

123. Guash A, Parham M, Zayas CF et al. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in African Americans with noninsulin dependent diabetes mellitus and nephropathy. J Am Soc Nephrol 1997; 8: 793798

124. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated metanalysis. Nephrol Dial Transplant 1995;10 [Suppl 9]: 3945

125. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851860

126. Marin R, Ruilope L M, Alijama P et al. A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. J Hypertens 2001; 19: 18711876

127. Remuzzi A, Imberti O, Puntorierei S et al. Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. Am J Physiol 1994; 267: F1034F1044

128. Agodoa LY, Appel L, Bakris GL et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 27192728

129. Blau A, Herzog D, Shechter P et al. Calcium channel blocker nisoldipine in chronicn renal failure. Ren Fail 1990; 12: 113119

130. Wetzels JF, Wiltink PG, Hoitsma AJ et al. Diuretic and natriuretic effects of nifedipine in healthy persons. Br J Clin Pharm 1988; 25: 547553

131. Hartmann A, Luno K, Holdaas H et al. Contrasting shortterm effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 1994; 5: 13851390

132. Kloke HJ, Wetzels JF, Koene RA et al. Effects of low dose nifedipine on urinary protein excretion rate in patients with renal disease. J Hypert 1997; 15 [Suppl 4]: 7578

133. Bakris GL, Weir MR, DeQuattro V et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54(4): 12831289

134. Benstein JA, Feiner HD, Ohsumi F et al. Impact of salt restriction and calcium antagonists on renal hypertrophy, function and sclerosis in rats with remnant kidneys (RK) and established injury. J Am Soc Nephrol 1992; 3: 734

135. Velussi M, Brocco E, Frigato F et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45(2): 216222

136. Ruggenenti P, Perna A, Benini R et al. Effects of dihydropyridine calcium channel blockers, angiotensin converting enzyme inhibition, and blood pressure control on chronic, nondiabetic nephropathies. J Am Soc Nephrol 1998; 9: 20962101

137. Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36: 646661

138. Hernan R, Balakuntalam S, Kasinath et al. About Angiotensin II and growth factors in the pathogenesis of diabetic nephropathy. Kidney Int 2002; 62(82): 815

139. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II –mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52(3): 1134

140. Locatelli F, Vecchio DL, Andrulli S et al. Role of combination therapy with ACE inhibitors and calcium channel blockers in renal protection. Kidney Int 2002; 62 (82): 5358

141. Ritz E, Orth SR, Strzelczyk P. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease. J Hypertens Suppl 1997; 15(2): 2126

142. Wenzel UO, Helmchen U, Schoeppe W et al. Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 1994;1: 114122

143. Amann K, Tцrnig J, Nichols C et al. Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Nephrol Dial Transplant 1995;10 [Suppl 9]: 3338

144. Brown S, Walton C, Crawford P et al. Long term effects of different antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 12101218

145. Mьnter K, Hergenrцder S, Jochims K et al. Individual and combined effects of verapamil or trandolapril on attenuating hypertensive glomerulopathic changes in the strokeprone rat. J Am Soc Nephrol 1996; 7: 681686

146. De Leeuw PW, Kroon AA. Fixed lowdose combination of an angiotensin converting enzyme inhibitor and a calcium channel blocker drug in the treatment of essential hypertension. J Hypertens 1997;15 [Suppl 2]: S39S42

147. Hemmelder MH, de Zeeuw D, de Jong PE. Antiproteinuric efficacy of verapamil in comparison to trandolapril in nondiabetic renal disease. Nephrol Dial Transplant 1999; 14(1): 98104

148. Messerli FH. Complementary actions and risk reduction: the rationale for combination of an angiotensin converting enzyme inhibitor with a nondihydropyridine calcium antagonist. J Hypertens 1997;15 [Suppl 2]: S35S38

149. Zuccala G, Onder G, Pedone C et al. Use of calcium antagonists and worsening renal function in patients receiving angiotensinconvertingenzyme inhibitors. Eur J Clin Pharmacol 2003; 58(10): 695669

150. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic man: Importance of therapeutic selection. Kidney Int 1992; 41: 898906

151. Dobronravov V, Karpov A. Effect of perindopril and its combination with verapamil on arterial renal blood flow velocity and proteinuria in type I diabetic patients with overt nethropathy. XVII Int Congress of Nephrology, Berlin, 2003

152. Добронравов ВА. Современные подходы к диагностике и лечению диабетической нефропатии (пособие для врачей). Нефрология 2003; (2): 93100

153. Boner G, Bernheim J, Chanard J et al. The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study. Nephrol Dial Transplant 2001; 16(11): 21582165

154. Petersen LJ, Petersen JR, Talleruphuus U et al. A randomised and doubleblind comparison of isradipin and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clin Nephrol 2001; 55: 375383

155. PROCOPA Study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized doubleblind trial. J Hypertens 2002; 20(4): 729737

156. The BErgamo NEphrologic DIabetes Complications Trial (BENEDICT): design and baseline characteristics.Control Clin Trials. 2003; 24(4): 442461

157. Boero R, Rollino C, Massara C et al. Verapamil versus amlodipine in proteinuric nondiabetic nephropathies treated with trandolapril (VVANNTT study): design of a prospective randomized multicenter trial. J Nephrol 2001; 14(1): 1518

158. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32[Suppl]: 112119

159. Islim IF, Watson RD, Ihenacho HN C et al. Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. Cardiology 2001; 96: 10181025

160. Mancini GB. Antiatherosclerotic effects of calcium channel blockers. Prog in Cardiovasc Dis 2002; 45(1): 120

161. Simon A, Levenson J. Effects of calcium channel blockers on atherosclerosis: new insights. Acta Cardiologica 2002; 57(4): 249255

162. The ENCORE Investigators Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary endothelial function). Circulation 2003; 107(3): 422428

163. Opie LH, Yusuf S, Kubler W. Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. Prog Cardiovasc Dis 2000; 43: 171—196

164. Pepine CJ, Faich G, Makuch R. Verapamil use in patients with cardiovascular disease: an overview of randomized trials. Clin Cardiol 1998; 21: 633—641

165. Steffen HM. Amlodipine in heart failure: first results from the PRAISE Study. Herz 1996; 20 [Suppl 2]: 3–4

166. Eguchi K, Kario K, Shimada K. Differential effects of a longacting angiotensin converting enzyme inhibitor (temocapril) and a longacting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. Hyper Research – Clin & Exper 2002; 25(3): 329333

167. Kestenbaum B, Gillen DL, Sherrard DJ et al. Calcium channel blocker use and mortality among patients with end stage renal disease. Kidney Int 2002; 61(6):21572164

168. Ruschitzka FT, Noll G, Luscher TF. Combination of ACE inhibitors and calcium antagonists: a logical approach. J Cardiovasc Pharmacol 1998; 31 [Suppl 2]: S5S16

Для цитирования:

Добронравов В.А., Царькова О.В. БЛОКАТОРЫ КАЛЬЦИЕВЫХ КАНАЛОВ В НЕФРОПРОТЕКЦИИ. Нефрология. 2004;8(1):7-21.

For citation:

Dobronravov V.A., Tsarkova O.V. CALCIUM CHANNEL BLOCKERS IN NEPHROLOGY. Nephrology (Saint-Petersburg). 2004;8(1):7-21. (In Russ.)

Просмотров: 140

ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)